HIGHLIGHTS
- who: Li Huang from the This cohort study set out to evaluate the safety and potential benefit of CP transfusion in critically ill patients with COVID- The sample size was calculated using PASS software (version, .0, NCSS, LLC. Kaysville, Utah, USA have published the research work: Convalescent plasma is of limited clinical benefit in critically ill patients with coronavirus disease-2019: a cohort study, in the Journal: (JOURNAL) of March/16,/2020
- what: Unlike other reports, 12 (50%) patients in the study had three or more comorbidities. In the study , no serious adverse event was . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.